Author(s): Hsieh, YY (Hsieh, Yao-Yuan); Chang, CC (Chang, Chi-Chen); Bau, DT (Bau, Da- Tian); Yeh, LS (Yeh, Lian-Shen); Tsai, FJ (Tsai, Fuu-Jen); Tsai, CH (Tsai, Chang-Hai)
Title: X-ray repair cross-complementing group 4 (XRCC4) promoter-1394*T-related genotype, but not XRCC4 codon 247/intron 3 or xeroderma pigmentosum group D codon 312,
751/promoter-114, polymorphisms are correlated with higher susceptibility to myoma Source: FERTILITY AND STERILITY, 90: 1417-1423 Suppl. 2 OCT 2008
Language: English Document Type: Article
Author Keywords: DNA repair; leiomyoma; polymorphism; xeroderma pigmentosum; XRCC4 KeyWords Plus: BREAST-CANCER RISK; LUNG-CANCER; XPD POLYMORPHISMS;
GENE XPD; COLORECTAL-CANCER; PANCREATIC-CANCER; GROUP-A; DNA;
POPULATION; CHEMOTHERAPY
Abstract: Objective: To investigate whether the DNA repair genes, X-ray repair cross- complementing group 4 (XRCC4) and xeroderma pigmentosum group D (XPD), could be useful markers for predicting leiomyoma susceptibility. Design: Prospective study. Setting:
Departments of gynecology and genetics in medical center. Patient(s): Women were divided into leiomyoma (n = 120) and nonleiomyoma groups (n = 112). Intervention(s): XRCC4 (codon 247, promoter-1394, intron 3) and XPD (codon 312, codon 75 1, promoter - 114)
polymorphisms were genotyped by polymerase chain reaction with restriction enzyme
digestions. Main Outcome Measure(s): Genotypes and allelic frequencies in both groups were compared. Result(s): XRCC4 promoter - 1394*T-related genotype/alleles were associated with higher susceptibility of leiomyoma. Proportions of XRCC4 promoter -1394*T
homozygote/heterozygote/G homozygote and T/G alleles were [1] 91.7%/6.7%/1.7% and 95%/5% and [2] 79.4%/17.9%/2.7% and 88.4%/11.6%, respectively. Five other single
nucleotide polymorphisms were not correlated with leiomyoma susceptibilities. Proportions of XRCC4 codon 247*CC/CA/AA and XRCC4 intron 3*Pi/ID/DD were [1] 95%/50%/0% and 72.5%/23.3%/4.2% and [2] 97.3%/2.7%/0 and 70.5%/24.1%/5.4%. Proportions of XPD codon 312*GG/GA/AA, XPD codon 75 1 *TT/TG/ GG, and XPD promoter -114*GG/GC/CC were [1]
65%/22.5%/12.5%, 92.5%/6.7%/0.8%, and 22.5%/46.7%/ 30.8%; and [2]
64.3%/22.3%/13.4%,92%/7.1%/0.9%, and 23.2%/46.4%/30.4%. Conclusion(s): XRCC4 promoter -1394*T-related genotype/alleles are associated with higher susceptibility of leiomyoma, whereas XRCC4 codon 247, XRCC4 intron 3, XPD codon 312, XPD codon 75 1, and XPD promoter - 114 polymorphisms are not correlated with its development.
Addresses: [Tsai, Fuu-Jen] China Med Univ Hosp, Dept Pediat & Med Genet, Grad Inst Chinese Med Sci, Taichung, Taiwan; [Hsieh, Yao-Yuan; Chang, Chi-Chen; Yeh, Lian-Shen]
China Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan; [Bau, Da-Tian; Tsai, Fuu- Jen; Tsai, Chang-Hai] China Med Univ Hosp, Dept Med Res, Taichung, Taiwan; [Tsai, Chang-
Hai] Asia Univ, Taichung, Taiwan
Reprint Address: Tsai, FJ, China Med Univ Hosp, Dept Pediat & Med Genet, Grad Inst Chinese Med Sci, 2 Yuh Der Rd, Taichung, Taiwan.
E-mail Address: [email protected]
Cited References: ALLENBRADY K, 2006, CANCER EPIDEM BIOMAR, V15, P1306, DOI 10.1158/1055-9965.EPI-05-0959.
BAU DT, 2004, CANCER RES, V64, P5013.
BROSENS I, 1996, FERTIL STERIL, V66, P376.
CAMPS C, 2003, CLIN LUNG CANCER, V4, P237.
COSTA S, 2007, BREAST CANCER RES TR, V103, P209, DOI 10.1007/s10549-006-9364-z.
CRAMER DW, 1992, SEMIN REPROD ENDOCR, V10, P320.
GAL TJ, 2005, LARYNGOSCOPE, V115, P2221, DOI 10.1097/01.mlg.0000183736.96004.f7.
GU JF, 2007, EMBO J, V26, P1010, DOI 10.1038/sj.emboj.7601559.
GUVEN M, 2007, MOL VIS, V13, P12.
HAN JL, 2005, CANCER EPIDEM BIOMAR, V14, P1539.
HOU SM, 2002, CARCINOGENESIS, V23, P599.
HSIEH YY, 2005, GENET MOL BIOL, V28, P661.
HU Z, 2004, LUNG CANCER-J IASLC, V46, P1, DOI 10.1016/j.lungcan.2004.03.016.
IDE F, 2003, AM J PATHOL, V163, P1729.
JIAO L, 2006, CANCER DETECT PREV, V30, P284, DOI 10.1016/j.cdp.2006.05.002.
JIAO L, 2007, CANCER LETT, V245, P61, DOI 10.1016/j.canlet.2005.12.026.
KENNON B, 2004, CLIN ENDOCRINOL, V61, P174, DOI 10.1111/j.1365-2265.2004.02073.x.
KHAN SG, 2002, NUCLEIC ACIDS RES, V30, P3624.
KIETTHUBTHEW S, 2006, INT J HYG ENVIR HEAL, V209, P21, DOI 10.1016/j.ijheh.2005.06.002.
KYO S, 1996, CLIN CANCER RES, V2, P2023.
LIANG G, 2003, INT J CANCER, V105, P669, DOI 10.1002/ijc.11136.
LIU G, 2007, CARCINOGENESIS, V28, P1254, DOI 10.1093/carcin/bgm020.
MASUTANI C, 1999, NATURE, V399, P700.
MECHANIC LE, 2006, CARCINOGENESIS, V27, P1377, DOI 10.1093/carcin/bgi330.
MEHTA PA, 2006, BLOOD, V107, P39.
OLSHAN AF, 2005, AM J MED GENET A A, V135, P268, DOI 10.1002/ajmg.a.30713.
PARK DJ, 2001, CANCER RES, V61, P8654.
PARK JY, 2002, CANCER EPIDEM BIOM 1, V11, P993.
REIN MS, 2000, ENVIRON HEALTH PE S5, V108, P791.
ROSELL R, 2003, SEMIN ONCOL S10, V30, P19, DOI 10.1016/S0093-7754(03)00281-1.
ROSELL R, 2004, SEMIN ONCOL S1, V31, P20, DOI 10.1053/j.seminoncol.2003.12.011.
RYBICKI BA, 2004, CANCER EPIDEM BIOMAR, V13, P23.
SCHABATH MB, 2005, CANCER EPIDEM BIOMAR, V14, P878.
SHINTANI S, 1999, CANCER RES, V59, P4142.
TAKAHASHI K, 2001, INT J ONCOL, V18, P1259.
TOMESCU D, 2001, CARCINOGENESIS, V22, P403.
TOWNSEND DE, 1970, AM J OBSTET GYNECOL, V107, P1168.
YEH CC, 2005, BMC CANCER, V5, ARTN 12.
Cited Reference Count: 38 Times Cited: 0
Publisher: ELSEVIER SCIENCE INC
Publisher Address: 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA ISSN: 0015-0282
DOI: 10.1016/j.fertnstert.2007.09.038 29-char Source Abbrev.: FERT STERIL ISO Source Abbrev.: Fertil. Steril.
Source Item Page Count: 7
Subject Category: Obstetrics & Gynecology; Reproductive Biology ISI Document Delivery No.: 358US
